Treatment of Restenosis and Stenosis with Dasatinib

Abstract

A method for treating or inhibiting artery obstructive disease, such as restenosis after angioplasty and stenting procedures and stenosis after coronary artery bypass surgery, in a subject by administering to the subject a therapeutically effective amount of dasatinib or a derivative thereof Also provided are drug-eluting medical devices, including stents, having a therapeutically effective amount of dasatinib.

1 . A method of treating restenosis or stenosis in a patient comprising administering to a patient in need of such treatment a composition comprising dasatinib or a pharmaceutically acceptable derivative thereof in an amount effective to treat restenosis or stenosis.  
   
   
       2 . The method according to  claim 1  wherein the effective amount ranges between about 35 and about 150 dasatinib per patient per day.  
   
   
       3 . The method according to  claim 1  wherein the effective amount ranges between about 35 and about 140 dasatinib per patient per day.  
   
   
       4 . The method according to  claim 1  wherein the effective amount ranges between about 70 and about 140 dasatinib per patient per day.  
   
   
       5 . The method according to  claim 1  wherein the dasatinib is administered orally.  
   
   
       6 . The method according to  claim 5  further comprising administering at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agents, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof  
   
   
       7 . The method according to  claim 1  further comprising administering to the patient one or more compounds that inhibit inflammation or smooth muscle cell proliferation.  
   
   
       8 . The method according to  claim 1  further comprising administering to the patient one or more additional therapeutic agents.  
   
   
       9 . The method according to  claim 8  wherein the one or more additional therapeutic agents is selected from the group consisting of sirolimus and paclitaxel.  
   
   
       10 . A method of treating artery obstructive disease in a patient comprising administering to a patient in need of such treatment a composition comprising dasatinib or a pharmaceutically acceptable derivative or analog thereof in an amount effective to treat artery obstructive disease.  
   
   
       11 . The method according to  claim 10  further comprising administering at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agents, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof  
   
   
       12 . The method according to  claim 10  wherein the effective amount ranges between about 35 and about 150 dasatinib per patient per day.  
   
   
       13 . The method according to  claim 10  wherein the effective amount ranges between about 35 and about 140 dasatinib per patient per day.  
   
   
       14 . The method according to  claim 10  wherein the effective amount ranges between about 70 and about 140 dasatinib per patient per day.  
   
   
       15 . The method according to  claim 10  wherein the dasatinib is administered orally.  
   
   
       16 . A stent having a coating comprising dasatinib or a pharmaceutically acceptable derivative thereof.  
   
   
       17 . The stent according to  claim 16  further comprising at least one additional therapeutic agent coated thereon.  
   
   
       18 . The stent according to  claim 17  wherein the additional therapeutic agent is selected from the group consisting of antiplatelet agents, antimigratory agents, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof.  
   
   
       19 . The stent according to  claim 17  wherein the additional therapeutic agent is sirolimus.  
   
   
       20 . The stent according to  claim 17  wherein the additional therapeutic agent is paclitaxel.  
   
   
       21 . A medical device comprising an implantable device having a coating comprising a therapeutic amount of dasatinib or a pharmaceutically acceptable derivative thereof for the site-specific, controlled release of the therapeutic amount.  
   
   
       22 . The medical device according to  claim 21  further comprising at least one additional therapeutic agent coated thereon.  
   
   
       23 . The medical device according to  claim 22  wherein the additional therapeutic agent is selected from the group consisting of antiplatelet agents, antimigratory agents, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof.  
   
   
       24 . A method of inhibiting restenosis or stenosis in a patient comprising administering to a patient in need of such treatment a composition comprising dasatinib or a pharmaceutically acceptable derivative thereof in an amount effective to inhibit restenosis or stenosis.  
   
   
       25 . The method according to  claim 24  wherein the effective amount ranges between about 35 and about 150 dasatinib per patient per day.  
   
   
       26 . The method according to  claim 24  wherein the effective amount ranges between about 35 and about 140 dasatinib per patient per day.  
   
   
       27 . The method according to  claim 24  wherein the effective amount ranges between about 70 and about 140 dasatinib per patient per day.  
   
   
       28 . The method according to  claim 24  wherein the dasatinib is administered orally.  
   
   
       29 . The method according to  claim 28  further comprising administering at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agents, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof.  
   
   
       30 . The method according to  claim 24  further comprising administering to the patient one or more compounds that inhibit inflammation or smooth muscle cell proliferation.  
   
   
       31 . The method according to  claim 24  further comprising administering to the patient one or more additional therapeutic agents.  
   
   
       32 . The method according to  claim 31  wherein the one or more additional therapeutic agents is selected from the group consisting of sirolimus and paclitaxel.